Tisagenlecleucel, a CD19-targeting G2 CAR-T cell product, was tested in 93 patients with DLBCL where it elicited robust efficiency (52%, ORR; 40%, CR; 12%, PR). This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.